Halozyme Therapeutics Management
Management criteria checks 3/4
Halozyme Therapeutics' CEO is Helen Torley, appointed in Jan 2014, has a tenure of 11.33 years. total yearly compensation is $12.74M, comprised of 7.5% salary and 92.5% bonuses, including company stock and options. directly owns 0.6% of the company’s shares, worth $39.44M. The average tenure of the management team and the board of directors is 3.3 years and 11.3 years respectively.
Key information
Helen Torley
Chief executive officer
US$12.7m
Total compensation
| CEO salary percentage | 7.53% |
| CEO tenure | 11.3yrs |
| CEO ownership | 0.6% |
| Management average tenure | 3.3yrs |
| Board average tenure | 11.3yrs |
Recent management updates
Recent updates
Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat
May 12Results: Halozyme Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
May 08
Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet
Apr 20Is Now The Time To Put Halozyme Therapeutics (NASDAQ:HALO) On Your Watchlist?
Mar 29Halozyme Therapeutics: Steady Growth In A Challenged Market
Mar 14Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Feb 21Halozyme Therapeutics, Inc. (NASDAQ:HALO) Might Not Be As Mispriced As It Looks
Jan 28Halozyme: Recent Approvals Alter My Appetite
Dec 31Halozyme Therapeutics (NASDAQ:HALO) Seems To Use Debt Rather Sparingly
Nov 28Halozyme: Fabless Or Not, The Stock Is Now A Steal On Evotec Deal
Nov 20Halozyme: Looking For More Growth Following Record Q3 Earnings
Nov 05Not Many Are Piling Into Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Yet
Oct 29Halozyme Therapeutics: Behind The Pullback
Oct 22
Extended Patent Protections And New Approvals Propel Revenue And Earnings Growth
Expanded patent coverage and new ENHANZE approvals open new market segments and extend royalty income, improving revenue and net margins.Halozyme Therapeutics, Inc.: Significantly Undervalued Growth Based On Current Fundamentals
Aug 14Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet
Aug 13Halozyme Therapeutics, Inc. (NASDAQ:HALO) Not Flying Under The Radar
Jul 17Halozyme Therapeutics: The Story Brightens
Jun 07Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics
Apr 10Halozyme Therapeutics: A Reasonable Value In An Overvalued Market
Jan 26CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | US$485m |
| Dec 31 2024 | US$13m | US$960k | US$444m |
| Sep 30 2024 | n/a | n/a | US$392m |
| Jun 30 2024 | n/a | n/a | US$337m |
| Mar 31 2024 | n/a | n/a | US$319m |
| Dec 31 2023 | US$12m | US$920k | US$282m |
| Sep 30 2023 | n/a | n/a | US$254m |
| Jun 30 2023 | n/a | n/a | US$234m |
| Mar 31 2023 | n/a | n/a | US$182m |
| Dec 31 2022 | US$10m | US$872k | US$202m |
| Sep 30 2022 | n/a | n/a | US$211m |
| Jun 30 2022 | n/a | n/a | US$366m |
| Mar 31 2022 | n/a | n/a | US$435m |
| Dec 31 2021 | US$7m | US$830k | US$403m |
| Sep 30 2021 | n/a | n/a | US$409m |
| Jun 30 2021 | n/a | n/a | US$229m |
| Mar 31 2021 | n/a | n/a | US$163m |
| Dec 31 2020 | US$7m | US$791k | US$129m |
| Sep 30 2020 | n/a | n/a | US$22m |
| Jun 30 2020 | n/a | n/a | -US$40m |
| Mar 31 2020 | n/a | n/a | -US$80m |
| Dec 31 2019 | US$6m | US$761k | -US$72m |
| Sep 30 2019 | n/a | n/a | -US$40m |
| Jun 30 2019 | n/a | n/a | -US$43m |
| Mar 31 2019 | n/a | n/a | -US$51m |
| Dec 31 2018 | US$6m | US$725k | -US$80m |
Compensation vs Market: Helen's total compensation ($USD12.74M) is above average for companies of similar size in the US market ($USD8.76M).
Compensation vs Earnings: Helen's compensation has been consistent with company performance over the past year.
CEO
Helen Torley (61 yo)
Dr. Helen I. Torley, M.B. Ch. B., M.R.C.P. has been Chief Executive Officer and President of Halozyme Therapeutics, Inc. since January 6, 2014. He serves as President, CEO & Director at Halozyme, Inc. Prio...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 11.3yrs | US$12.74m | 0.60% $ 39.4m | |
| Senior VP & CFO | 3.3yrs | US$4.22m | 0.026% $ 1.7m | |
| Senior VP | 3.3yrs | US$5.39m | 0.023% $ 1.5m | |
| Chief Operations Officer | 1.6yrs | no data | no data | |
| Head of Investor Relations & Corporate Communications | 3.3yrs | no data | no data | |
| Chief Human Resources Officer | 5.3yrs | no data | no data | |
| Chief Commercial Officer | 2yrs | no data | no data | |
| Chief Business Officer | 1.8yrs | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
Experienced Management: HALO's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 11.3yrs | US$12.74m | 0.60% $ 39.4m | |
| Independent Chair of the Board | 9.8yrs | US$544.82k | 0.023% $ 1.5m | |
| Member of the Scientific Advisory Board | 20.8yrs | no data | no data | |
| Independent Director | 2.3yrs | US$485.26k | 0.0075% $ 497.4k | |
| Member of the Advisory Board | no data | no data | no data | |
| Chairman of Scientific Advisory Board | 11.3yrs | US$68.17k | no data | |
| Member of Scientific Advisory Board | 20.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 19.8yrs | no data | no data | |
| Independent Director | 12.2yrs | US$475.04k | 0.057% $ 3.8m | |
| Independent Director | 1.1yrs | US$437.51k | 0.0053% $ 349.7k | |
| Independent Director | 3.2yrs | US$455.04k | 0.017% $ 1.1m | |
| Independent Director | 6.7yrs | US$470.04k | 0.038% $ 2.5m |
Experienced Board: HALO's board of directors are seasoned and experienced ( 11.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/23 04:14 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Halozyme Therapeutics, Inc. is covered by 34 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| James Birchenough | Barclays |
| Robert Wasserman | Benchmark Company |